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Introduction {#sec1}
============

Human immunodeficiency virus type 1 (HIV-1) is the main causative agent of acquired immunodeficiency syndrome (AIDS). Although HIV-1 has spread throughout the world over a few decades, the other human AIDS virus, HIV-2, is largely confined to West Africa ([@bib9]) and appears to be steadily declining in prevalence ([@bib9]). HIV-1 and HIV-2 arose as a result of cross-species transmission of distinct simian immunodeficiency virus (SIV): HIV-1 from SIV infecting chimpanzees and gorillas in central Africa and HIV-2 from SIV infecting sooty mangabeys in West Africa ([@bib4]). There are striking differences in the natural history of infection between HIV-1 and HIV-2. The great majority of HIV-1-infected patients will progress to AIDS and death if not treated with anti-retroviral therapy (ART), but a small fraction (0.15%) maintains viral loads below detection and normal CD4+ T cell counts, termed elite controllers or long-term non-progressors ([@bib32]). In contrast, a much larger group of HIV-2-infected subjects (37% of a community HIV-2 cohort in Guinea-Bissau) experiences long-term viral control, which appears to be clinically stable, unlike HIV-1 infection ([@bib46]). Nevertheless, most HIV-2-infected subjects will progress to AIDS without treatment, with a clinical picture indistinguishable from HIV-1 ([@bib37]).

The differences in the natural history of infection with HIV-1 and HIV-2 could result from host or viral factors or, more likely, from a combination of the two. Although there are clear immune correlates of HIV-2 non-progression, such as the gag-specific CD8+ T cell response ([@bib10]), other studies suggest that specific viral factors could play an important role ([@bib33]). HIV-2 elicits a potent broadly neutralizing antibody response in most infected people, leading to speculation that HIV-2 envelope might be one of the key factors accounting for the reduced pathogenicity of HIV-2. However, the structure of HIV-2 gp120 was recently determined and showed remarkable similarities to HIV-1 gp120 ([@bib8]). This led us to consider other viral factors that may explain the clinical differences between HIV-1 and HIV-2. The retroviral accessory protein Nef is a potential contributing factor, since it is relevant in HIV and SIV replication and pathogenesis and functional differences between HIV-1 and HIV-2 Nef have been reported ([@bib30]). Deletions in Nef are clearly linked with low viral load and delayed disease progression in both primates and humans ([@bib11], [@bib21], [@bib24], [@bib31]). Despite its small size, HIV-1 (206 residues), HIV-2 (256 residues), and SIVmac (263 residues) Nef display a plethora of functions, including downregulation of membrane proteins such as CD3, CD4, CD28, and MHC class I and II molecules by mediating sorting systems with phosphofurin acidic cluster sorting protein 1 and 2 (PACS-1 and -2) ([@bib3], [@bib14], [@bib39], [@bib41], [@bib42], [@bib44]) and the adaptor proteins 1 and 2 (AP-1 and -2) complexes, upregulation of the invariant chain (Ii) associated with immature MHC class II complexes ([@bib39], [@bib42]), up-regulation of the Fas protein on infected cells ([@bib48]), modulation of signaling pathways through interactions with kinases ([@bib26]), and increasing the infectivity of virus particles by counteracting the host restriction factors SERINC3/5 ([@bib35], [@bib45]).

Although many of these functions are broadly conserved among HIV-1, HIV-2, and SIV Nefs, there are some differences in Nef functions among retrovirus families. For example, most HIV-2 and SIV Nefs can downregulate the T cell receptor (TCR)-CD3 complex by clathrin adaptor protein complex 2 (AP-2)-mediated endocytosis, but HIV-1 and its precursor SIV (SIVcpz and SIVgor) Nefs have lost this ability: this is thought to be a key factor promoting the chronic immune activation observed in HIV-1 infection ([@bib38]). HIV-2 and most SIV Nefs downregulate the co-stimulatory molecule, CD28, much more efficiently than those of HIV-1 and its precursors ([@bib30], [@bib38]). Furthermore, although HIV-1 Nef binds to the SH3 domain of some kinases, such as Fyn, Lck, and Hck, with high affinity, HIV-2 and SIVmac Nef do not possess this ability, but are still able to bind to full-length Hck ([@bib6], [@bib15], [@bib26]). In addition to these functional differences, HIV-2 Nef and most SIV Nefs appear to employ different mechanisms from HIV-1 Nef to mediate the same functions. For example, HIV-2 and SIVmac Nef use their C-terminal region, which is absent in HIV-1 Nef, to downregulate MHC class I molecules by binding to the AP-1 complex ([@bib30], [@bib43]). Similarly, HIV-1 and HIV-2 Nefs have been shown to use overlapping but distinct domains to upregulate Ii ([@bib30]).

Although substantial progress has been made in understanding the structural aspects of HIV-1 and SIV Nefs ([@bib1], [@bib19], [@bib23], [@bib34]), no structures of HIV-2 Nef were resolved to date that might help to explain the key differences between HIV-1 and HIV-2 function. Here, we present the crystal structure of the core region of HIV-2 Nef, based on a primary viral sequence derived from an HIV-2-infected subject from the Caio HIV-2 community cohort, Guinea-Bissau. HIV-2 Nef possesses an additional C-terminal α-helix that is present in HIV-2 and SIV Nefs but absent in HIV-1 ([@bib23], [@bib28]). Only one structure of SIV Nef construct harboring this C-terminal region was recently determined as a complex with AP-2 by cryo electron microscopy (EM), showing essentially a very similar C-terminal helix ([@bib49]). Here we also prepared and crystallized the core domain of SIVmac Nef, including the C-terminal region. The crystal structure of SIVmac Nef also showed a C-terminal helix.

Results {#sec2}
=======

Crystal Structures of HIV-2 Nef {#sec2.1}
-------------------------------

HIV-2 Nef proteins (wild-type and C193Y mutant) were expressed in *Escherichia coli* as soluble proteins and purified to show a single peak by size exclusion chromatography as a monomer ([Figure S1](#mmc1){ref-type="supplementary-material"}A). HIV-2 Nef C193Y mutant was crystallized as described in [Methods](#sec4){ref-type="sec"} and diffracted to 2.07 Å ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Of note, the C193Y mutation on HIV-2 Nef did not alter the overall structure in solution, confirmed by CD spectra ([Figure S1](#mmc1){ref-type="supplementary-material"}D). The structure of HIV-2 Nef protein was solved by molecular replacement using the HIV-1 structure (PDB: [1AVV](pdb:1AVV){#intref0010}) and refined to the final model with good stereochemistry ([Table 1](#tbl1){ref-type="table"}). The core structure of HIV-2 Nef consists of five α-helices (α2, α3, α5, α6, α7) and two β-strands (β1, β2) ([Figures 1](#fig1){ref-type="fig"}A and 1C). Comparison with the structures of HIV-1 Nef (1AVV \[[@bib2]\], sequence identity 46%) and SIVmac Nef (3IK5 \[[@bib23]\], sequence identity 70%) resulted in root-mean-square deviation (RMSD) values of 0.674 Å and 0.580 Å, respectively, demonstrating that the overall structure of HIV-2 Nef is almost identical to those of both the HIV-1 and SIVmac Nefs ([@bib23], [@bib27]) ([Figures 1](#fig1){ref-type="fig"}B--1D). The electron density of the N-terminal region (residues 90--103) and part of the central loop (residues 182--185 and 199--202) of HIV-2 Nef was disordered, as previously reported in HIV-1 and SIVmac Nef structures ([@bib2], [@bib23]). However, unlike most of the existing Nef crystal structures, part of the central loop was resolved and forms an α-helix (α4). This was visualized because its di-leucine motif (ExxxLϕ) EANYLL interacts with the hydrophobic crevice formed by α2 and α3 of a neighboring Nef molecule, stabilizing the otherwise flexible loop ([Figure S2](#mmc1){ref-type="supplementary-material"}A). This helix structure of the central loop has been observed in some other Nef structures, where interactions with either the adaptor protein 2 (AP-2) or the Nef protein itself stabilize the complex ([@bib17], [@bib28], [@bib34]).Table 1Date Collection and Refinement StatisticsStatisticHIV-2 NefSIVmac Nef**Data Collection**X-ray sourcePF BL-5APF BL-17AResolution (Å)44.77-2.07 (2.13-2.07)41.6-2.00 (2.05-2.00)Wavelength (Å)1.00000.9800Space group*P*2~1~2~1~2~1~*P6*~*5*~22Cell dimensions a, b, c (Å)a = 43.58,a = 72.53,b = 44.77,b = 72.53,c = 103.64c = 111.09Total reflections91696229843Unique reflections1292212304Mean (*I*/*σ* (*I*))24.1 (2.6)20.0 (3.2)Redundancy7.1 (7.2)18.7 (18.9)Completeness (%)99.9 (99.5)100 (100)*R*~merge~0.055 (0.779)0.112 (1.035)CC (1/2)1.000 (0.799)0.999 (0.874)**Refinement***R*~work~ (%)20.519.5*R*~free~ (%)24.024.1No. of protein residues141154RMSD bonds (Å)0.00230.0049RMSD angles (˚)0.550.55Ramachandran Favored (%)98.699.3 Allowed (%)1.40.7 Outlier (%)00Average B factor (Å^2^)43.732.6[^3][^4]Figure 1Crystal Structures of HIV-1, HIV-2, and SIVmac Nef Proteins(A) Alignment of the Nef sequences of HIV-1, HIV-2, and SIVmac Nefs. The rods and arrows above the sequences indicate α-helix and β-sheet, respectively.(B and C) (B) Structure of HIV-1 Nef (PDB ID: [1AVV](pdb:1AVV){#intref0030}). (C) Structure of HIV-2 Nef.(D) Structure of SIVmac239 Nef.(B--D) Each structure is shown in Ribbon-model from the same orientation. Dotted circles indicate distinct structures determined in HIV-2 and SIVmac Nefs.

HIV-2 Nef Contains a Conserved C-terminal Alpha Helix {#sec2.2}
-----------------------------------------------------

An additional C-terminal α-helix (α8) was observed in HIV-2 Nef ([Figure 1](#fig1){ref-type="fig"}C dotted square). This structure is wholly absent in the HIV-1 protein. Ser237 in the loop between α7 and α8 helices forms a hydrogen bond with the main chain amine group of Leu239 to make an ST turn ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). This ST turn is often seen at the N-terminus of α-helices as a helix cap ([@bib13], [@bib47]). Glu241 forms a hydrogen bond with Tyr235 and the highly conserved Lys245 ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}B). The interaction between side chains of charged residues three to four positions apart, introducing charged residues on an adjacent turn of the α-helix, seems to increase the helix propensity. Arg251 makes a hydrogen bond network with His161, Glu231, and Glu232 to fix the α-helix in its place ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}C). Finally, Trp244 and Leu248 of the C-terminal helix are centrally located in a hydrophobic environment consisting of Glu231, Glu232, Tyr235, Glu241, Lys245, Ile253, and Phe255, making this helix fixed in the core structure ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}D). Fifty three HIV-2 group A Nef sequences obtained from the Los Alamos National Laboratory (LANL) HIV Sequence Database were analyzed by WebLogo ([@bib7]) ([Figure 2](#fig2){ref-type="fig"}C), revealing that many residues are conserved in this C-terminal region. A helical wheel display of the C-terminal helix demonstrates that the highly conserved hydrophobic residues Trp244 and Leu248, together with Glu241 and Arg251, are located at the interface with the core structure ([Figure 2](#fig2){ref-type="fig"}D). In addition, the ST turn residues are also highly conserved. Taken together, these results suggest that the C-terminal structure is a conserved feature of HIV-2 Nef.Figure 2C-terminal Structures of HIV-2 and SIVmac Nefs(A and B) Important residues for the C-terminal helix structure in HIV-2 and SIVmac Nefs. In each figure, residues involved are shown in stick model. The dotted line in yellow indicates a hydrogen bond.(C) Amino acid conservation of the C-terminal residues of HIV-2. Sequences of HIV-2 A from Los Alamos HIV database were aligned and the conservation of each C-terminal residue was analyzed by WebLogo. Residue number for HIV-2 was based on Nef from present study.(D) Helical wheel display of the consensus sequence of HIV-2 Nef C-terminal α-helix (residue: 241--251).

SIVmac Nef Also has the C-terminal Helix {#sec2.3}
----------------------------------------

Amino acid sequence alignment indicates that key residues of α8 helix of HIV2 Nef are essentially conserved with SIVmac Nef ([Figure 1](#fig1){ref-type="fig"}A). Although several crystal structures of SIVmac Nef core-domain structures have previously been resolved, the C-terminal region was removed prior to crystallization in all cases ([@bib23], [@bib28]). On the other hand, the cryo EM structure of SIVmac Nef complexed with AP-2 recently reported that it has a C-terminal helix (some residues between residues 235 and 250) ([@bib49]). Here, the core domain of SIVmac Nef protein harboring the C-terminal region was prepared in a similar way to HIV-2 Nef ([Figure S1](#mmc1){ref-type="supplementary-material"}E). The SIVmac Nef crystals diffracted to 2.0 Å ([Figures S1](#mmc1){ref-type="supplementary-material"}Fand S1G). The structure was determined by molecular replacement using HIV-2 Nef as a search model ([Table 1](#tbl1){ref-type="table"}).

The SIVmac Nef core structure is essentially the same as the reported truncated version of SIVmac Nef and similar to HIV2 Nef (RMS deviation of 0.43 Å for an overlay of 92 Cα atoms, [Figures 1](#fig1){ref-type="fig"}C,1D, and [S2](#mmc1){ref-type="supplementary-material"}C). The C-terminal α-helix (α8) was found in the present "full core" SIVmac Nef similarly to HIV2 Nef ([Figure 1](#fig1){ref-type="fig"}D dotted square). SIVmac Nef has more residues in the C-terminal region than HIV-2 Nef and the additional residues form a short α-helix (α9) ([Figure 1](#fig1){ref-type="fig"}D dotted triangle and [Figure S3](#mmc1){ref-type="supplementary-material"}E). Although detail description and PDB data are not currently available, similar helix formation was also presented in the recent paper of cryo EM structure of its AP-2 complex ([@bib49]). The ST turn, the hydrogen bond network, and Val244 and Leu248 buried in a hydrophobic environment ([Figures 2](#fig2){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}F--S3H) closely resemble the HIV-2 Nef structure. These strongly conserved features suggest the functional significance of this structure, not only in HIV-2 but also in SIVmac Nefs.

HIV-2 Nef Interacts with Di-leucine Sorting Motif in the Common Binding Mode {#sec2.4}
----------------------------------------------------------------------------

EANYLL (residues 190--195), the di-leucine motif of HIV-2 Nef, interacts with the hydrophobic crevice formed by the α2 and α3 helices, as shown in [Figures 3](#fig3){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}A. This di-leucine motif is flexible but forms an α-helix (α4) when bound to the hydrophobic crevice, enabling two critical residues, Glu190 and Leu194, to align on the same side ([Figure 3](#fig3){ref-type="fig"}A). Glu190 interacts with a highly conserved Arg137 residue ([Figure 3](#fig3){ref-type="fig"}A). On the other hand, the two leucine residues of the motif, Leu194 and Leu195, fit into the hydrophobic crevice as follows ([Figure 3](#fig3){ref-type="fig"}B): Leu194 binds to the center of the crevice contacting Leu129, Met132, Arg138, Ile141, and Leu142, and the second leucine of the motif, Leu195, is deeply accommodated into the upper side of the crevice consisting of Ile123, Leu129, Leu142, Tyr145, and Leu146. Notably, a recent report of the SIVmac Nef structure ([@bib28]) showed that the di-leucine sorting motif binds to the crevice formed by the α2 and α3 helices, similar to the current HIV-2 Nef structure ([Figures 3](#fig3){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C), presumably reflecting the same sorting mechanism for CD3 and CD4 downregulation of HIV2 and SIVs.Figure 3Common Binding of Sorting Motifs(A--D) Key residues involved in the interaction are shown in stick model. Each structure (A, C, and D) is displayed from the same angle, whereas that of (B) is close-up view of (A) from different angle. (A and B) Structure of di-leucine motif (green) and the hydrophobic crevice of HIV-2 Nef. (C) Structure of di-leucine motif (orange) and the hydrophobic crevice of SIVmac239 Nef (light blue) (PDB: [5NUI](pdb:5NUI){#intref0035}). (D) Structure of CD3 zeta chain (light-orange) and the hydrophobic crevice of SIVmac239 Nef (light grey) (PDB: [3IK5](pdb:3IK5){#intref0040}).(E) Alignment of the sorting motifs.

HIV-2 Nef has the Capacity to Interact with the CD3 Zeta Chain {#sec2.5}
--------------------------------------------------------------

The previously reported crystal structure of SIVmac complexed with the sorting motif of CD3 zeta chain further suggested that the binding mode of the motif is similar to those of the di-leucine motifs in HIV-2 and SIV Nefs ([Figures 3](#fig3){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}D) ([@bib23]). Although the helical structure of CD3 zeta chain in SIVmac is tilted compared with that of the di-leucine motifs of HIV-2 and SIVmac Nefs, critical residues are rearranged so as to be located in the similar positions for the counterpart residues of the motifs ([Figures 3](#fig3){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}). Amino acid sequences of the motifs are different ([Figure 3](#fig3){ref-type="fig"}E) but they form an α-helix so that key glutamic acids interact with arginine residue(s) and two hydrophobic residues fit into the hydrophobic crevice ([Figure 3](#fig3){ref-type="fig"}). This raises the possibility that HIV-2 Nef has the ability to bind to the CD3 zeta chain in a similar way to SIVmac Nef. Indeed, HIV-2 Nef was previously reported to interact with CD3 zeta chain at a cellular level ([@bib36]); however, the molecular basis for this interaction was poorly understood. Here, the binding of HIV-2 Nef with the CD3 zeta chain was investigated by isothermal titration calorimetry (ITC) measurements. The consensus HIV-1 and HIV-2 Nef proteins were prepared by the same method as HIV2 Nef ([Figures 4](#fig4){ref-type="fig"}A and [S5](#mmc1){ref-type="supplementary-material"}A), and a peptide was synthesized based on the previous studies, encompassing the second ITAM motif of CD3 zeta chain, termed SNID2. The ITC experiment showed that the dissociation constant of SIVmac Nef with the SNID2 peptide was 5.0 μM (ΔG = −7.2 kcal/mol, ΔH = −14.2 kcal/mol, TΔS = −7.0 kcal/mol, Ν = 1.05), which is in good agreement with the previous result ([@bib28]) ([Figure 4](#fig4){ref-type="fig"}D). As expected, no binding was observed for HIV-1 Nef ([Figure 4](#fig4){ref-type="fig"}B). On the other hand, HIV-2 Nef interacts with the peptide with a dissociation constant of 12.0 μM (ΔG = −6.8 kcal/mol, ΔH = −12.3 kcal/mol, TΔS = −5.5 kcal/mol, Ν = 1.08) ([Figure 4](#fig4){ref-type="fig"}C). This result provides the direct evidence that HIV-2 Nef can interact with the CD3 zeta chain without any additional factor *in vitro*.Figure 4Interactions of Nef with CD3 ζ(A) Amino acid sequence alignment of the residues involved in CD3 ζ binding.(B) No binding was observed for HIV-1 consensus Nef.(C) HIV-2 consensus Nef interacted with CD3 ζ with a dissociation constant of 12.0 μM.(D) SIVmac239 Nef interacted with CD3 ζ with the highest affinity 5.0 μM.

Previously, an I132T mutation on HIV-2 Nef was shown to abrogate its ability to downregulate CD3 ([@bib22]). Here we introduced the same mutation to the best binding Nef, SIVmac Nef, to evaluate its effects on CD3 zeta chain binding. The SIVmac I132T Nef mutant showed modest heat generation but the binding constant could not be determined ([Figure S5](#mmc1){ref-type="supplementary-material"}B). This suggests that Nef indeed interacts with the CD3 zeta chain using its hydrophobic crevice. In addition to the I132T mutation, a double mutation (I123L/L146F) has also been reported to disrupt the interaction of Nef with the CD3 zeta chain, resulting in loss of CD3 downregulation ([@bib40]). The ITC experiment demonstrated that this mutation greatly disrupts the ability of Nef to interact with the CD3 zeta chain, even though slight residual binding tendency was retained ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Of note, both I132T and I123L/L146F mutations do not cause any overall structural changes, revealed by CD spectra ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E). Together with the functional data on I132T and I123L/L146F mutations, these suggest that Nef needs to interact with the CD3 zeta chain with a dissociation constant in the μM range to achieve CD3 downregulation.

Structural Comparison of Src-family Kinase Binding Sites on Nefs Explains Distinct Affinities {#sec2.6}
---------------------------------------------------------------------------------------------

HIV-2 and SIVmac Nefs lack the ability to bind to the SH3 domain of Hck, one of the strongest interaction partners for HIV-1 Nef ([@bib15], [@bib20], [@bib26]). On the other hand, SIVmac Nef can bind to the SH3 domains of Fyn and Src, whereas HIV-1 Nef can also bind to them but more weakly than Hck ([@bib6]). HIV-2 and SIVmac Nefs exhibit different preferences for binding SH3 domains from HIV-1. The proline-rich motif (PxxPxR) on HIV-1 Nef is essential for binding to the SH3 domain of Src family kinases and is conserved among HIV-1, HIV-2, and SIVmac Nefs ([Figure 1](#fig1){ref-type="fig"}A). The HIV-1 Nef utilized for crystal structure of its complex with Hck is derived from HIV-1 SF2 strain, which has an insertion of four amino acids ahead of the core region in comparison with HIV-1 consensus sequence. Thus, here, we use the numbering of HIV-1 residues based on the SF2 strain. The main differences lie in residues Thr121, Gln122, and Tyr124 in HIV-1 Nef, which are represented by Glu149, Glu150, and Ile152, respectively, in HIV-2 and SIVmac sequences ([Figure 1](#fig1){ref-type="fig"}A). Among these residues, Tyr124 has been shown to play a critical role in the binding to the SH3 domain of Src kinases in a previous mutational study ([@bib5]). Tyr124 in HIV-1 Nef directly interacts with Arg81, making the conformation of PxxPxR motif suitable for recognition by Trp114 of the SH3 domain, which is conserved in all Src family kinases ([Figure 5](#fig5){ref-type="fig"}A). On the other hand, Tyr124 also forms a hydrophobic pocket together with Met83, contributing to make hydrophobic interaction with Ile92 of the SH3 domain. In contrast, the equivalent residue in HIV-2 and SIVmac, Ile152, does not seem capable of contributing sufficiently in either fashion ([Figures 5](#fig5){ref-type="fig"}C and 5E). This critical amino acid difference accounts for the weak binding of HIV-2 and SIVmac Nefs to SH3 domains of Src family kinases.Figure 5Distinct Src-Family Kinase Binding Affinity(A) HIV-1 Nef (PDB ID: [4U5W](pdb:4U5W){#intref0045}) complexed with the SH3 domain of Hck is shown in Ribbon model. Amino acid residues are based on the HIV-1 SF2 strain, which has four residues insertion ahead of the core region.(B) HIV-1 Nef complexed with Hck (PDB ID: [4U5W](pdb:4U5W){#intref0050}). The surface of HIV-1 Nef is colored based on the calculated potentials from −3.0 kT/e (red) to +3.0 kT/e (blue). Amino acid residues are based on the HIV-1 SF2 strain, which has four residues insertion ahead of the core region.(C, E, and G) Zoomed-in view in HIV-2 Nef (C), SIVmac Nef (E), and SIVmac Nef complexed with HCK I92W mutant (PDB ID: [5NUH](pdb:5NUH){#intref0055}) (G).(D, F, and H) Electrostatic potential representation of HIV-2 Nef (D), SIVmac Nef (F), and SIVmac Nef complexed with HCK I92W mutant (H).

The electrostatic aspects of the HIV-1 Nef structure demonstrated a positively charged surface for SH3 domain binding ([Figure 5](#fig5){ref-type="fig"}B). In contrast, this surface in HIV-2 and SIVmac Nefs is negatively charged because of the presence of Glu149 and Glu150 residues ([Figures 5](#fig5){ref-type="fig"}D and 5F). This electrostatic presentation might explain why HIV-2 and SIVmac Nefs show a preference for binding to Fyn and Src kinases, which have a positively charged residue at position 92. On the other hand, the SIVmac Nef was successfully crystallized as its complex with the I92W mutant of HCK kinase, which has higher affinity ([@bib28]), showing some different recognition mode ([Figures 5](#fig5){ref-type="fig"}G and 5H). Trp92 of HCK faces vertically to Phe122 of Nef, pushing the surrounding residues far from Glu149 and Glu150 (Nef), while a saltbridge between Asp96 (HCK) and Arg81 (Nef) is maintained. These amino acid differences between HIV-1 and HIV-2/SIV Nefs have an effect on the preference of the SH3 domain binding, but it is also worth noting that that the distinct pattern of the amino acid differences overlaps with the residues responsible for CD3 binding, suggesting that although HIV-2 and SIVmac Nef do not possess the capacity to bind strongly to the SH3 domain of Src family kinases, they retained the ability to interact with the CD3 zeta chain instead.

N-terminal Acidic Cluster Interacts with the Hydrophobic Crevice in SIVmac Nef {#sec2.7}
------------------------------------------------------------------------------

In the present study, the structure of the N-terminal acidic cluster (residues 91--96, corresponding to residues 59--64 in HIV-1) of SIVmac Nef was determined ([Figure 1](#fig1){ref-type="fig"}D, dotted pentagon and [Figure 6](#fig6){ref-type="fig"}). The N-terminal region includes an acidic cluster and interacts with the hydrophobic crevice formed by the α2 and α3 helices of a neighboring Nef molecule, which is utilized for binding to the di-leucine motif in HIV-2 Nef ([Figure S2](#mmc1){ref-type="supplementary-material"}B), whereas the central loop of SIVmac Nef (residues 180--210) containing the motif was disordered. Interestingly, N-terminal residues are extended in a direction toward the α2, but not the α3, helix ([Figures 6](#fig6){ref-type="fig"}A and 6B). Upon binding to the hydrophobic crevice, a part of the acidic cluster forms a short α-helix, allowing Ile90 and Asp94 to align in the same direction ([Figure 6](#fig6){ref-type="fig"}A). The previous report of crystal structure of HIV-1Nef complexed with its protein inhibitor demonstrated that the N-terminal acidic cluster forms a longer helix with Trp57, preceding the N-terminal acidic cluster, accommodating into the hydrophobic pocket ([@bib50]) ([Figure 6](#fig6){ref-type="fig"}C). This recognition mode is somehow distinct from that of shorter helix with extended conformation in the present structure of SIVmac Nef ([Figure 6](#fig6){ref-type="fig"}B), which harbors aspartic acid at the site corresponding to Trp57 (this construct does not include this residue). Notably, this binding in the current structure comprises of more extended interaction with six acidic residues in the current structure and is very similar to those of sorting motifs observed in [Figure 3](#fig3){ref-type="fig"}; (1) Asp94 forms a saltbridge with Arg137 and (2) Ile90 fits into the hydrophobic crevice consisting of Ile123, Gly128, Leu129, Arg138, Ile141, and Leu142. This could be a common feature explaining how Nef accommodates its binding partner into the hydrophobic crevice. In addition to these interactions, other acidic residues (Asp91, Glu92, Glu93, Asp95, and Asp96) also contribute to the binding, mainly by contacting the positively charged surface ([Figure 6](#fig6){ref-type="fig"}B). The recent cryo-EM structure of HIV-1 Nef complexed with AP-1 and the crystal structure of the complex of AP-1 μ subunit revealed that acidic cluster forms an extended conformation to interact widely with the positively charged surface of the adjacent μ subunit ([Figure 6](#fig6){ref-type="fig"}D) ([@bib19], [@bib29]). The present structure, however, showed another conformation of this region of Nef, implying that it may assume multiple conformations depending on the situation.Figure 6Structural Plasticity of the N-terminal Acid Cluster(A) Binding of the acidic-cluster (orange) with the hydrophobic crevice of neighboring Nef. Side chains of residues involved in the interaction are shown in stick model and labeled.(B) Binding of the acidic cluster (orange) with the hydrophobic crevice of neighboring Nef in surface model. Side chains of residues are shown in stick model. The surface of SIVmac Nef is colored based on the calculated potentials from −5.0 kT/e (red) to +5.0 kT/e (blue).(C) Binding of the acidic cluster (salmon pink) with the hydrophobic crevice in HIV1 in complex with engineered Hck-SH3 domain (PDB ID: [3REA](pdb:3REA){#intref0060}). The surface of HIV1 Nef is colored as same as (B).(D) Different conformation of acidic-cluster of Nef. Acidic cluster of HIV-1 Nef (cyan) is shown in stick model, and it forms extended conformation along with the positive charged surface of m subunit (PDB ID: [4EN2](pdb:4EN2){#intref0065}). The surface of m subunit is colored as same as (B).

Discussion {#sec3}
==========

Here we present the crystal structures of HIV-2 and SIVmac Nefs to demonstrate their "full" core regions. The overall structure of HIV-2 Nef is essentially similar to those of both HIV-1 and SIVmac, emphasizing the importance of their core structures. The present HIV-2 Nef structure also revealed how its di-leucine motif binds to a hydrophobic crevice formed by the α2 and α3 helices, providing the binding modes conserved with SIV Nefs. Furthermore, an additional C-terminal helix was found in both HIV-2 and SIVmac Nefs and is essentially conserved between HIV-2 and SIVmac Nefs, implying its functional significance.

Comparison of the present structure with that of SIVmac Nef bound to the CD3 zeta chain gave us important insights into how HIV-2 Nef interacts with the motif of the CD3 zeta chain. Three critical residues, Glu190 and two hydrophobic residues, Leu194 and Leu195, in the di-leucine motif of Nef and Glu74, Leu75, and Leu77 in CD3 zeta chain, are located at the same binding sites for each residue despite their different sequential order ([Figure 3](#fig3){ref-type="fig"}). The glutamic acid residues, Glu190 in Nef and Glu74 in the CD3 zeta chain, strongly interact with well-conserved arginine residues Arg137 and Arg138. The previous mutagenesis study revealed that these residues are relevant for the ability of HIV-2 and SIVmac Nefs to downmodulate CD3 ([@bib28]). Two hydrophobic residues of the di-leucine motif LL in HIV-2 and CD3 zeta chain (LNL) fit into the deep crevice. As expected by structural analysis together with the previous study on CD3 zeta chain binding ([@bib28]), the ITC experiment here showed that HIV-2 Nef binds the CD3 zeta chain with a similar dissociation constant to SIVmac Nef. The I132T or I123L/L146F mutations greatly reduce the affinity, emphasizing the importance of the intricate features of the crevice. This result also indicates that direct interaction between Nef and CD3 zeta chain with μM order of dissociation constant is required for CD3 downregulation.

Despite its overall similarity, the present structures provide insight into the underlying reasons for the differential affinities to the SH3 domain of HIV-1, HIV-2, and SIVmac Nefs, which were also pointed out by Collette et al. using the homology models ([@bib6]). Although the proline-rich motif and other residues involved in the interaction with the SH3 domain are well conserved, Thr121, Gln122, and Tyr124 in HIV-1 Nef (The numbering of resides is based on the SF2 strain) are systematically represented by Glu149, Glu150, and Ile152 in HIV-2 and SIVmac, respectively. These different residues completely change the characteristics of the binding sites for the SH3 domain, leading to the loss of the ability to bind to the SH3 domain of Hck and different preferences for Fyn and Src kinases. However, SIVmac Nef has evolved to interact with Hck via a different mechanism ([@bib15]). Its close relative HIV-2 Nef, whose putative SH3-binding site structurally resembles that of SIVmac, likely uses a similar binding mechanism. The fact that Nefs target the same kinases in different ways emphasizes their importance for the virus lifecycle *in vivo*.

The present SIVmac Nef structure revealed the structure of the flexible N-terminal acidic cluster by interacting with the hydrophobic crevice as observed in [Figure 3](#fig3){ref-type="fig"}A. The structure formed an α-helix so that Ile90 and Asp94 can be aligned to make important interactions ([Figure 6](#fig6){ref-type="fig"}A). Furthermore, other acidic residues strengthen the interaction with the positively charged surface of the crevice ([Figure 6](#fig6){ref-type="fig"}B). The way that this hydrophobic crevice accommodates the motifs share a lot in common and the crevice has been used to interact with various binding partners, for example binding the cytoplasmic tail of CD4. The di-leucine motif of the CD4 cytoplasmic tail is necessary for its downregulation by HIV-1, HIV-2, and SIV Nefs ([@bib18]). Likewise, the di-leucine motif of CD28 is essential for its downregulation ([@bib44]). As observed in the binding with CD3 zeta chain, this hydrophobic crevice might play a role in binding to the cytoplasmic tail of CD28 and result in the different potencies of its downregulation by HIV-1 and HIV-2/SIVmac Nefs. Furthermore, although the N-terminal region interacts with the crevice of its neighboring Nef, the N-terminus orients toward the α2 helix and this binding can happen intermolecularly. Indeed, a previous NMR structural study showed that the flexible N-terminus binds to its crevice in solution ([@bib16]). Of note, the acidic cluster has been implicated in PACS binding and the hydrophobic crevice was recently suggested as the likely binding site ([@bib12]). Therefore, Nef might accommodate the N-terminal acidic cluster until it finds its correct binding partner such as PACS. This model was proposed some time ago, and the present structure might help our understanding of how Nef accommodates its flexible N-terminus and hides the multi-binding "hub," the hydrophobic crevice.

In this study, a C-terminal structural element (α8) is revealed. The residues at the α8 helix and its surrounding region are well conserved not only in HIV-2 but also in SIVmac Nefs, suggesting a strong evolutionary pressure, implying functional significance. The importance of the additional C-terminus of Nef was previously demonstrated by an investigation showing that a SIVmac strain harboring C-terminally truncated Nef was able to recover its virulence by obtaining additional C-terminal residues, comparable with that of SIVmac239 Nef ([@bib25]). It has also previously been shown that deletion of the C-terminal residues of HIV-2 and SIVmac239 Nef specifically inhibits their ability to downregulate MHC-I without abrogating other functions. MHC-I downregulation by HIV-2 and SIVmac Nefs is not as dependent on their proline-rich motifs as is HIV-1 Nef ([@bib30], [@bib43]). The present study allows us to provide a possible explanation for this difference. Firstly, the downregulation of MHC-I involves the activation of Src-family kinases; however, activation is not dependent on the proline-rich motif of HIV-2 and SIVmac Nefs. Therefore, this step does not seem to be critical for the difference. On the other hand, the crystal structure of HIV-1 Nef in complex with the MHC-I cytoplasmic tail and the μ1 subunit of the adaptor protein 1 (AP-1) demonstrates extensive interactions of the proline-rich motif of HIV-1 Nef with the MHC-I tail. The recent cryo-EM structures of the HIV-1 Nef/AP-1 complex and HDX-MS analysis indicate that these tight interactions contribute to the open conformer of AP-1/HIV-1 Nef/MHC-I complex trimers, fitting to the clathrin pathway. When HIV-2 and SIVmac Nefs are superimposed on the HIV-1 Nef/MHC-I tail/μ1 subunit complex, the C-terminal structure can be seen to encapsulate the μ1 subunit without any steric hindrance ([Figures 7](#fig7){ref-type="fig"} and [S6](#mmc1){ref-type="supplementary-material"}). The C-terminal residues of HIV-2 and SIVmac Nefs could therefore provide an additional binding site to strengthen the AP-1 complex formation. This result raises the possibility that the C-terminal region tightly and/or suitably binds to AP-1 complex to induce an open conformer suitable for entry into the clathrin pathway.Figure 7Models of AP-1 Complexes with HIV-2 and SIVmac Nefs Based on Crystal Structure of HIV-1 Nef Complexed with AP-1 μ Subunit and Cytoplasmic Tail of MHC Class I Molecule(A) HIV-1 Nef (cyan) in complex with MHC-I CD (yellow) and the μ1 subunit of AP-1 (dark blue) (PDB [4EN2](pdb:4EN2){#intref0070}).(B and C) Superimposition of HIV-2 Nef (B) and SIVmac Nef (C) onto MHC-I CD and μ1 subunit of AP1.

The present study provides another insight into the functional differences at a molecular level between HIV-1, HIV-2, and SIVmac Nefs. HIV-2 and SIVmac Nefs share the similar features including the C-terminal structure, unexpectedly discovered here, to play important roles in virus replication and immune evasion. Several differences, however, are still known between HIV-2 and SIVmac Nefs, such as the requirement for the CD4 tail for its downmodulation ([@bib18]). Future studies of the neglected N-terminal and C-terminal regions of Nefs, exhibiting relatively poor conservation among different lentiviruses, will further reveal the precise mechanisms of immune evasion, which in turn should significantly contribute to the design of effective anti-HIV therapies and vaccines.

Limitations of the Study {#sec3.1}
------------------------

We found here the C-terminal helix region in HIV2 Nef protein, which is conserved with that of SIVmac Nef. Together with the previous study revealing that the deletion of this region restored the downregulation of MHC class I molecules, we speculated that this structural feature is involved in AP-1-mediated downregulation. Therefore, further investigation for this hypothesis should be examined. Moreover, the possibility that this region may have additional physiological significance should be examined.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

The accession number for the atomic coordinates of HIV2 Nef and SIVmac Nef proteins reported in this paper is PDB: [6K6M](pdb:6K6M){#intref0015} and [6K6N](pdb:6K6N){#intref0020}.
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Document S1. Transparent Methods and Figures S1--S6
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